Metformin

Caroline Day; Clifford J. Bailey

doi:10.1016/B978-008055232-3.62140-3

Metformin

Caroline Day^*
, Clifford J. Bailey

^*Corresponding author for this work

Aston University

Research output: Chapter in Book/Published conference output › Chapter (peer-reviewed) › peer-review

1 Citation (Scopus)

Abstract

Metformin is the only biguanide antihyperglycemic agent used in the treatment of type 2 (non-insulin dependent) diabetes mellitus. It counters insulin resistance partly by increased insulin action (so-called insulin sensitizing effects) and partly via actions that are not directly insulin dependent. Metformin reduces hepatic glucose output by suppression of gluconeogenesis and glycogenolysis. In skeletal muscle, metformin increases insulin-mediated glucose uptake and glycogen storage. Other actions of metformin that contribute to its blood glucose-lowering effect are reduced fatty acid oxidation and increased glucose turnover, the latter occurring particularly in the splanchnic bed .... © 2007

Original language	English
Title of host publication	xPharm
Subtitle of host publication	the comprehensive pharmacology reference
Editors	S.J. Enna, David B. Bylund
Publisher	Elsevier
Number of pages	4
ISBN (Print)	978-0-08-055232-3
DOIs	https://doi.org/10.1016/B978-008055232-3.62140-3
Publication status	Published - 1 Dec 2011

Access to Document

10.1016/B978-008055232-3.62140-3

Cite this

@inbook{bd2dee723ce9401da195893414b0eade,

title = "Metformin",

abstract = "Metformin is the only biguanide antihyperglycemic agent used in the treatment of type 2 (non-insulin dependent) diabetes mellitus. It counters insulin resistance partly by increased insulin action (so-called insulin sensitizing effects) and partly via actions that are not directly insulin dependent. Metformin reduces hepatic glucose output by suppression of gluconeogenesis and glycogenolysis. In skeletal muscle, metformin increases insulin-mediated glucose uptake and glycogen storage. Other actions of metformin that contribute to its blood glucose-lowering effect are reduced fatty acid oxidation and increased glucose turnover, the latter occurring particularly in the splanchnic bed .... {\textcopyright} 2007",

author = "Caroline Day and Bailey, \{Clifford J.\}",

year = "2011",

month = dec,

day = "1",

doi = "10.1016/B978-008055232-3.62140-3",

language = "English",

isbn = "978-0-08-055232-3",

editor = "S.J. Enna and Bylund, \{David B.\}",

booktitle = "xPharm",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Metformin

AU - Day, Caroline

AU - Bailey, Clifford J.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Metformin is the only biguanide antihyperglycemic agent used in the treatment of type 2 (non-insulin dependent) diabetes mellitus. It counters insulin resistance partly by increased insulin action (so-called insulin sensitizing effects) and partly via actions that are not directly insulin dependent. Metformin reduces hepatic glucose output by suppression of gluconeogenesis and glycogenolysis. In skeletal muscle, metformin increases insulin-mediated glucose uptake and glycogen storage. Other actions of metformin that contribute to its blood glucose-lowering effect are reduced fatty acid oxidation and increased glucose turnover, the latter occurring particularly in the splanchnic bed .... © 2007

AB - Metformin is the only biguanide antihyperglycemic agent used in the treatment of type 2 (non-insulin dependent) diabetes mellitus. It counters insulin resistance partly by increased insulin action (so-called insulin sensitizing effects) and partly via actions that are not directly insulin dependent. Metformin reduces hepatic glucose output by suppression of gluconeogenesis and glycogenolysis. In skeletal muscle, metformin increases insulin-mediated glucose uptake and glycogen storage. Other actions of metformin that contribute to its blood glucose-lowering effect are reduced fatty acid oxidation and increased glucose turnover, the latter occurring particularly in the splanchnic bed .... © 2007

UR - https://www.scopus.com/pages/publications/84883912390

U2 - 10.1016/B978-008055232-3.62140-3

DO - 10.1016/B978-008055232-3.62140-3

M3 - Chapter (peer-reviewed)

SN - 978-0-08-055232-3

BT - xPharm

A2 - Enna, S.J.

A2 - Bylund, David B.

PB - Elsevier

ER -

Metformin

Abstract

Access to Document

Other files and links

Fingerprint

Biguanides

Ciglitazone

Pioglitazone

Cite this